According to a research report titled ‘Global Sepsis Diagnostics Market 2021-2028’, available with MarketStudyReport, global sepsis diagnostics market is anticipated to grow at a CAGR of 8.18% during 2021-2028.
 

Rising cases of hospital-acquired infections among patients, in consort with increasing prevalence of sepsis are major factors fueling the global sepsis diagnostics market growth. Furthermore, government initiatives for sepsis related R&D activities are creative new opportunities for the industry.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3754652/
 

However, expensive instruments, and reimbursement issues may stifle the market outlook over the forecast period.
 

On the basis of diagnostic method, the industry is divided into conventional diagnostics, and automated diagnostics. Based on product terrain, the marketplace is bifurcated into blood culture media, instruments, and assay kits & reagents.
 

In terms of technology terrain, global sepsis diagnostics market is branched into microbiology, molecular diagnostics, immunoassay, and others. With respect to pathogen, the industry is classified into fungal sepsis, gram-positive & gram-negative bacterial sepsis, and others. Speaking of testing type, the market is split into laboratory testing, and point of care testing.
 

Considering geographical aspect, the market spans across Asia-Pacific, North America, Latin America, Europe, and Middle East & Africa. Among these, Asia Pacific market is expected to witness a rapid growth during the forecast period. The expansion is attributed to swift economic development, and medical system advancements in China and India. Moreover, high mortality rate due to sepsis disease, along with rising awareness about sepsis diagnosis & treatment are enlarging the APAC industry share.
 

The major players in global sepsis diagnostics market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company (CR Bard), Abbott Laboratories, Luminex Corporation, CytoSorbents Corporation, T2 Biosystems Inc., F. Hoffmann-La Roche AG, Bruker Corporation, bioMérieux S.A., EKF Diagnostics, Immunexpress Inc., and Response Biomedical Corp.